Magnesium-Based Trigger Point Injections for Relief of Chronic Myofascial Pelvic Pain
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This study will be a randomized, controlled, double-blinded, single-centre superiority trial
with two parallel groups. The primary outcome will be average myofascial pelvic pain in the
two weeks following final injection treatment as assessed using the visual analogue scale.
Randomization will be performed as block randomization with a 1:1 allocation ratio,
stratified based on opioid use at the time of study enrollment. In total, 60 participants
will be recruited and randomized, with 30 being assigned to each treatment arm. The study
will be restricted such that none of the participants enrolled will be current concomitant
opioid users (for any reason) and will not have used opioid drugs within the 3 months
preceding enrollment in the study.
A third non-randomized arm of 30 participants who are on the waiting list for the chronic
pain clinic will be enrolled and compared to the two randomized arms. Among this patient
population and in the setting of the Chronic Pain Clinic it was determined that it would not
be acceptable to randomize participants to a no-treatment control group. As such, an active
treatment is being used as comparator in the randomized trial. In order to assess
participants in the absence of treatment this third non-randomized arm will serve as a
no-treatment control group.
Eligibility criteria for this third arm is the same as the main study, except for the
restriction by opioid use status. Participation in this third arm will not exclude a
participant from randomization into one of the two main arms of the study. Therefore, across
the three arms, up to 90 patients will be enrolled in this study.
Phase:
Phase 3
Details
Lead Sponsor:
Queen's University
Collaborators:
Hotel Dieu Hospital Kingston General Hospital Kingston Health Sciences Centre